Rebif
information and resources from the National Cancer Institute
NCI Thesaurus | Rebif
(Other name for: recombinant interferon beta)NCI Thesaurus | Rebif
(Other name for: recombinant interferon beta)
|
|
|
|
news articles
Serono reverses sale plan and seeks buys 01 Apr 2006
Telegraph.co.uk, However, the company's attractiveness has been in doubt, with its top-selling multiple sclerosis drug, Rebif, facing the prospect of growing competition, while ...
Tysabri poised for return to market 01 Apr 2006
Pharmaceutical Business Review ...interferon beta- 1b), Teva Neuroscience's Copaxone (glatiramer acetate), Serono SA's Novantrone (mitoxantrone hydrochloride) and Serono/Pfizer's Rebif (r-IFN ...
Serono still confident MS drug Rebif will achieve market ... Mar 9, 2006
Forbes ZURICH (AFX) - Serono SA said it remains confident of achieving market leadership with its key multiple sclerosis treatment Rebif despite yesterday's vote by ...
Serono still believes Rebif will be MS leader Mar 9, 2006
Reuters ZURICH, March 9 (Reuters) - Swiss biotech firm Serono (SEO.VX: Quote, Profile, Research) still believes that its multiple sclerosis drug Rebif will be the ...
POST OF THE DAY Mar 31, 2006
Motley Fool Avonex is less expensive, less effective, more painful to administer, but at least better than Copaxone and Rebif in that regard as it is only a once a week ...
Serono's Board of Directors to Propose an Increase in Authorized ... Mar 30, 2006
Yahoo! News (press release) The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel(R )/Ovitrelle®, Serostim®, Saizen®, Zorbtive(TM) and Raptiva®. ...
Tysabri delayed as rivals gird Mar 22, 2006
Boston Globe, ...recommend that the FDA allow Tysabri to be sold again, Serono SA, the Swiss biopharmaceutical giant, was girding for renewed competition for its MS drug, Rebif ...
“Out of Zion shall go forth medicines� Mar 1, 2006
Globes, Michel Revel of the Weizmann Institute, who headed the team that discovered multiple sclerosis treatment Rebif, talks about what Israel has to do to become a ...
Tysabri Likely To Come Back Despite Delay Mar 22, 2006
newratings.com 0903 GMT [Dow Jones] Serono +0.2% at CHF928, little moved despite news the FDA extended the regulatory review of Tysabri, a competitor to its leading drug Rebif ...
Serono in turmoil as Glaxo quits bid Mar 11, 2006
Business Online, ...competition. Rebif, its key multiple sclerosis treatment, will be forced to fight for market leadership with Elan Corporation’s Tysabri. ...
Serono shares slip as hopes of Glaxo bid fade Mar 13, 2006
Reuters ...of US biotech firm Biogen Idec Inc's (BIIB.O: Quote, Profile, Research) multiple sclerosis drug Tysabri, putting pressure on Serono's competing drug Rebif. ...
Serono under pressure as Tysabri decision nears Mar 8, 2006
Reuters Quote, Profile, Research) (ELN.I: Quote, Profile, Research) and had been seen as a strong competitor for Serono's market-leading multiple sclerosis drug, Rebif ...
Schering defeat seen forcing German Merck to act Mar 27, 2006
Reuters Merck declined to comment when asked if it could look at Serono, whose most important drug is Rebif, a multiple sclerosis treatment that rivals Schering's ...
Serono faces new US action over Serostim Mar 26, 2006
ABC News Serono, the world's No. 3 biotech company, is best known for its multiple sclerosis drug Rebif and is a leader in infertility treatment.
Serostim continues to haunt Serono Mar 26, 2006
Swissinfo, Serono, the world's number 3 biotechnology company, is best known for its multiple sclerosis drug Rebif and is a leader in infertility treatment. ...
MS is a part of my life, but not my whole life Mar 27, 2006
Scotsman, I take Rebif 44 which is a beta interferon and with every visit to the gym - I do pilates and yoga to help my balance, although the treadmill is no longer an ...
Wonder drugs don’t exist for MS; stick with proven options Mar 26, 2006
Fort Wayne Journal Gazette, Interferon beta-1b (Betaseron), interferon beta-1a (Avonex, Rebif), glatiramer (Copaxone), and mitoxantrone (Novantrone) are only partially effective in the ...
Serono's Main Threat Isn't Tysabri -Lombard Mar 9, 2006
newratings.com 0915 GMT [Dow Jones]--Serono's (SRA) Rebif sales are likely to see only minimal impact from the near-certain return of Tysabri to market, says Lombard Odier ...
Glaxo pulls out of Serono bidding: report Mar 12, 2006
Herald News Daily, GlaxoSmithKline‘s lower price. A Food and Drug Administration - ), putting pressure on Serono‘s competing Rebif drug. Tysabri was pulled ...
Biogen, Elan Shares Jump After Getting US Support on Tysabri Mar 9, 2006
Bloomberg ...with a strong warning label, Tysabri may have sales of more than $1 billion a year, stealing revenue from rival products such as Serono SA's Rebif and Schering ...
Swiss shares close off lows in thin trade helped by Wall St gains ... Mar 22, 2006
Forbes If relaunched on the market, Elan and Biogen's rival MS drug Tysabri would be a major competitor for Serono's MS drug Rebif, which makes up half of the Swiss ...
Reefer Relief Mar 23, 2006
LongIslandPress.com, Ironically, Jesse, who says that Rebif, his MS medicine, feels like “battery acid� in his veins, worries what would happen if the government did regulate ...
FDA asks panel to weigh benefits, risks of Tysabri Mar 6, 2006
MarketWatch ...relapse rate "appears to be twice the benefit of currently available first-line treatments for MS," which also include Serono SA's (SRA) Rebif, Betaseron, by ...
FDA panel to weigh benefits, risks of Tysabri Mar 6, 2006
MarketWatch ...twice the benefit of currently available first-line treatments for MS." Other first-line treatments include Serono SA's (SRA) Rebif, Betaseron, by Berlex Inc ...
Elan Shares Jump After US Advisory Panel Backs Tysabri Mar 9, 2006
Bloomberg When introduced in November 2004, Tysabri was sold for about $23,500 a year, 34 percent more than Serono SA's Rebif, at the time the most expensive MS treatment ...
MS Guessing Game Heats Up Mar 9, 2006
TheStreet.com Other players in the MS market include Switzerland's Serono (SRA:NYSE ADR - commentary - research - Cramer's Take) which makes Rebif and Novantrone, Israel's ...
Glaxo pulls out of Serono bidding Mar 12, 2006
Reuters.uk, ...of the multiple sclerosis drug Tysabri, made by US biotech firm Biogen (BIIB.O: Quote, Profile, Research), putting pressure on Serono's competing Rebif drug. ...
Swiss shares higher in thin morning trade tracking Wall Street Mar 13, 2006
Forbes ...was the only major loser, down 21.50 sfr or 2.3 pct at 898, on continuing worries about a relaunch of Tysabri in the US, a rival of its key MS-treatment Rebif. ...
Glaxo pulls out of Serono bidding: report Mar 12, 2006
MSN Money ...week recommended the reintroduction of the multiple sclerosis drug Tysabri, made by US biotech firm Biogen , putting pressure on Serono's competing Rebif drug. ...
Swiss shares close higher on Wall St gains, led by Kudelski UPDATE Mar 9, 2006
Forbes ...recovering from yesterday's weakness on concerns about a return to market of Elan and Biogen's MS drug Tysabri, posing a threat to Serono's main product, Rebif ...
Swiss shares close higher in thin trade tracking Wall Street ... Mar 10, 2006
Forbes ...pct at 72.50 sfr, while Serono decreased 6.50 sfr to 919.50, amid concern about the possible relaunch of Tysabri, a rival to the group's key Rebif MS treatment ...
Swiss shares higher in thin morning trade on technical rebound led ... Mar 9, 2006
Forbes ...withdrawn on safety fears last year. The product is a rival of Serono's key MS treatment Rebif. Banking stocks were led by Julius ...
Biogen says Tysabri, new pill to keep it MS leader Mar 10, 2006
Reuters Rival multiple sclerosis drug maker Serono (SEO.VX: Quote, Profile, Research) hopes to become global market leader thanks to demand for its Rebif product but ...
Swiss shares higher ahead of Wall St opening bell, led by Kudelski Mar 9, 2006
Forbes ...withdrawn on safety fears last year. The product is a rival of Serono's key MS treatment Rebif. Among heavyweights, Nestle was up ...
Pfizer says it plans to continue shopping spree Mar 7, 2006
MSNBC Shedlarz said Pfizer aims to be a major force in biotechnology, fueled by partnerships such as one involving Serono SA’s multiple sclerosis drug Rebif. ...
UPDATE 1-Pfizer targets deals under $4 bln -vice chairman Mar 7, 2006
Reuters ...to be a major force in biotechnology, fueled by partnerships such as one involving Serono SA's (SEO.VX: Quote, Profile, Research) multiple sclerosis drug Rebif ...
Cholesterol drug hopes boost Astra Mar 8, 2006
Guardian Unlimited, Analysts said this was potentially bad news for Serono's MS treatment Rebif. It also means a bid for the company from Glaxo is now unlikely. ...
Chinese cap weighs down metals sector Mar 7, 2006
Guardian Unlimited, All of which would be good news for Serono, the Swiss biotech that makes leading MS drug Rebif and is rumoured to be a takeover target for GlaxoSmithKline, up ...
Brokers get light-headed over BOC Mar 1, 2006
Guardian Unlimited, Serono makes Rebif, a leading multiple sclerosis drug, and if Tysabri does not return to the market or is restricted, then the Swiss firm could be bid for by ...
Ratiopharm: competes with Stada, Sandoz on biogeneric drugs Mar 8, 2006
MarketWatch Rebif is another version of Interferon beta, sold by Swiss company Serono SA (SEO.VX). It saw 2005 sales of EUR1.066 billion, up 16.4% on the year.
Tysabri Return To Market: First-Line Use In Relapsed Multiple ... Mar 8, 2006
FDA Advisory Committee ...with MS who have not tried any of the other available first-line therapies (beta interferon (Biogen Idec’s Avonex, Serono/Pfizer’s Rebif, Berlex/Chiron’s ...
Elan is buffeted and I'm buying Mar 6, 2006
MSN Money ...sales. Rebif, another competitor to Tysabri, generated $1.2 billion -- almost 50% of Serono (SRA, news, msgs) ’s revenue in 2005. ...
ZKB Reads Tysabri Recommendation To Serono Mar 9, 2006
newratings.com The read-across for Serono's (SRA) Rebif is clearly negative, says ZKB, although stock had already dropped 3.1% in Wednesday trade. ...
Thu: For Teva's sake Mar 16, 2006
Globes, ...and with the possible addition of Tysbari, there will be five competitors in the field: Teva with Copaxone; Serono (NYSE:SRA; SWX:SEO) with Rebif, which it ...
Tysabri FDA Decision Determines Serono Future Mar 3, 2006
New Ratings The FDA meeting on Tysabri from March 7 to March 8 will clarify the long-term outlook for its main drug Rebif and thus for Serono's value, if a sale is a real ...
Protein lab test could spot MS early Mar 14, 2006
LabTechnologist.com, Interferon beta-1a (Avonex or Rebif) and interferon beta-1b (Betaferon) are used for some people who have the relapsing and remitting form of the disease. ...
Biogen Idec says it's rebounding strongly Mar 13, 2006
Boston Globe, ...is administered in a once-a-month intravenous infusion, compared to more frequent injections for Avonex, Biogen Idec's existing MS drug, and Rebif, a treatment ...
Tysabri should return to market, says FDA panel Mar 9, 2006
Pharma Times (subscription), ...also said the drug should not be used in combination with other MS drugs, such as Biogen Idec's own Avonex (interferon beta-1a), Serono's Rebif (interferon beta ...
Biogen foresees Tysabri re-launch by June Mar 9, 2006
Investor's Business Daily (subscription) Most of the current leading therapies -- Serono's Rebif, Biogen's Avonex, and Schering AG's Betaseron -- must be administered by needle more frequently than ...
Drug stocks decline, Vertex falls on drug data Mar 9, 2006
Investor's Business Daily (subscription) Serono (SRA), which markets the MS drug Rebif, was up 1% at $17.51, while Teva Pharmaceutical Industries (TEVA), which sells Copaxone, fell 1% to $40.68. ...
Two-Day Tysabri Hearing Drawing Intense Attention Mar 3, 2006
BioWorld Online (subscription), Idec), Betaseron (beta interferon 1b, from Berlex Laboratories Inc.), Copaxone (glatiramer acetate, from Teva Pharmaceuticals Inc.) and Rebif (beta interferon ...
BioMarin and Serono Announce Positive Results From Phase 3 ... Mar 15, 2006
PR Newswire (press release), The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R)/Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R ...
Manhattan Research Reveals Top Ten Consumer-Ranked Pharmaceutical ... Mar 7, 2006
PR Newswire (press release), NuvaRing, Ortho Evra, Ortho Tri-Cyclen Lo, Patanol, Paxil, Plavix, Premarin, Prevacid, Procrit, Protonix, Provigil, Pulmicort, Raptiva, Rebif, Relpax, Remicade ...
BioMarin and Serono Announce Positive Results From Phase 3 ... Mar 15, 2006
Yahoo! News (press release) The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel® /Ovitrelle®, Serostim®, Saizen®, Zorbtive(TM) and Raptiva®. ...
Google gloom causes FTSE hits galore Feb 28, 2006
Guardian Unlimited, If the regulator allows Tysabri to return to the market with no restrictions it could pose a serious competitive threat to Rebif, Serono's biggest-selling drug ...
Serono Announces Formal Conclusion of Serostim Settlement Dec 15, 2005
PharmaLive.com (press release), The company's US products are Rebif(R) (interferon beta-1a), Novantrone(R) (mitoxantrone for injection concentrate), Gonal-f(R) (follitropin alfa for injection ...
MS is unpredictable disease Dec 8, 2005
Georgetown Record, ...hopeful.As recently as 1993, there were no FDA approved drugs for the treatment of MS.Now, there are five (Avonex, Betaseron, Copaxone, Rebif, and Novantrone ...
Serono's Suitors Nov 22, 2005
Corante Their recent growth has been due to Rebif, a recombinant beta-interferon for multiple sclerosis, but before that one of their big products was Serostim. ...
More deals expected from acquisitive Novartis Dec 9, 2005
Reuters ...of Serono, investors have worried about the lack of strong late-stage drug candidates in the firm's pipeline, and its reliance on multiple sclerosis drug Rebif ...
Elan Tysabri Expected: May Still Boost Shrs Nov 18, 2005
New Ratings ...to simply being re-approved) is slim." That said, expects Serono (SRA) and Schering (SCH.XE) to be weaker due to their exposure to MS via Rebif and Betaseron ...
Serono declines comment on report bids due early next yr Dec 2, 2005
Forbes It has one blockbuster product, MS drug Rebif, which makes up around half of its revenues, and analysts have said that its pipeline of new treatments is weak. ...
Bids for Swiss Serono due early next year -sources Dec 2, 2005
Reuters ...itself from a low-margin maker of fertility drugs into Europe's leading biotech business, driven by strong demand for its multiple sclerosis product Rebif. ...
Biotech Earnings Jump In Quarter Nov 21, 2005
Chemical & Engineering News Its main revenue driver was the MS treatment Rebif, which now accounts for 55% of overall revenues after posting 19.8% higher sales in the quarter. ...
Missouri City woman's diagnosis leads way to her passion Nov 29, 2005
Fort Bend Southwest Sun, You need to get on medicine, I don't care what they get on, but they need to be on something." Since Tucker has been on Rebif, an FDA-approved drug used in the ...
Yachtsman Bertarelli seeks new course for Serono Nov 18, 2005
Reuters The turnaround came with the launch of blockbuster multiple sclerosis treatment Rebif, to this day the company's leading product and the main driver of growth ...
|
|
